Targeting prion amyloid deposits in vivo

Area of Science:

• Neuroscience
• Biochemistry
• Medical Imaging

Background:

• Diagnosing human prion diseases is difficult due to the absence of sensitive, non-invasive tests.
• Amyloid deposition is a hallmark of several prion diseases, including variant Creutzfeldt-Jakob disease (vCJD) and Gerstmann-Sträussler-Scheinker (GSS) syndrome.

Purpose of the Study:

• To investigate the potential of amyloid-targeting ligands, specifically methoxy-X04, for direct in vivo imaging of amyloid deposits in prion diseases.
• To evaluate methoxy-X04 as a novel diagnostic tool for prion diseases characterized by amyloid pathology.

Main Methods:

• In vivo transcranial two-photon microscopy was used to image PrP amyloid plaques in mice infected with the 87V scrapie strain after systemic methoxy-X04 administration.
• Methoxy-X04's ability to detect PrP amyloid deposits was also assessed on cerebellar tissue sections from GSS patients.

Main Results:

• Methoxy-X04 successfully labeled PrP amyloid plaques in the brains of both presymptomatic and symptomatic infected mice.
• Real-time imaging demonstrated clear distinction of PrP amyloid deposits within 15 minutes of intravenous methoxy-X04 injection.
• The ligand exhibited rapid clearance from non-amyloid brain regions.
• PrP amyloid deposits were also detectable in GSS patient cerebellar sections upon direct methoxy-X04 application.

Conclusions:

• Amyloid-targeting ligands like methoxy-X04 can effectively image PrP amyloid deposits in prion diseases.
• This imaging strategy holds potential for developing new diagnostic methods for human prion diseases associated with amyloid pathology.
• Methoxy-X04 and its derivatives could serve as PET imaging agents to enhance prion disease diagnosis.